Indian Journal of PsychiatryIndian Journal of Psychiatry
Home | About us | Current Issue | Archives | Ahead of Print | Submission | Instructions | Subscribe | Advertise | Contact | Login 
    Users online: 253 Small font sizeDefault font sizeIncrease font size Print this article Email this article Bookmark this page
Search Again
 Back
 Table of Contents
 
 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Article Access Statistics
 Reader Comments
 Email Alert
 Add to My List
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1413    
    Printed51    
    Emailed2    
    PDF Downloaded241    
    Comments [Add]    

Recommend this journal

 
ORIGINAL ARTICLE
Year : 2004  |  Volume : 46  |  Issue : 4  |  Page : 333-341

Escitalopram Versus Citalopram And Sertraline : A Double-Blind Controlled, Multi-Centric Trial In Indian Patients With Unipolar Major Depression


1 Department of Clinical Research, Torrent Research Centre, Village Bhat, Dist. Gandhinagar-382 428, India
2 Department of Psychiatry, St. John’s Medical college & Hospital, Bangalore, India
3 Consultant Psychiatrist, Goa, India
4 Department of Psychiatry, Rajiv Gandhi Medical college & Chattrapati shivaji Hospital, Thane, India
5 Consultant Psychiatrist & Psychotherapist, Delhi Psychiatry center, Delhi, India
6 Consultant Psychiatrist, Manobal Klinik, Delhi, India
7 Department of Psychiatry, Madras medical college & research institute, Chennai, India
8 Consultant Psychiatrist, M.S. Chellamuthu Trust & Research foundation, Madurai, India
9 Consultant psychiatrist, Woodland Asha Neuro Psychiatric center, Hyderabad, India
10 Department of Psychiatry, N.R.S. Medical College, Kolkatta, India
11 Department of Psychiatry, K. G. Medical College Lucknow, India
12 Department of Psychiatry, B.J. medical College and Civil hospital, Ahmedabad, India

Correspondence Address:
Vaya Lalit
Department of Clinical Research, Torrent Research Centre, Village Bhat, Dist. Gandhinagar-382 428
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


PMID: 21206792

Rights and PermissionsRights and Permissions

The present randomized, double blind, parallel group, controlled, multi-centric trial was designed to evaluate the efficacy and tolerability of escitalopram in comparison with citalopram and sertraline in the treatment of major depressive disorder. Outpatients (N=214) with an ongoing/newly diagnosed ICD-10 major depressive episode and a Hamilton Rating Scale for Depression (HAM-D) score of > 18 were randomly assigned to citalopram, 20– 40 mg/day (74 patients), escitalopram, 10– 20 mg/day (69 patients) and sertraline, 50-150 mg/day (71 patients), for a 4-week double-blind treatment period, with dosage adjustment (after 2 weeks of treatment) according to the response to treatment. Clinical response was evaluated by the 17 items HAM-D and the Clinical Global Impression (CGI) scales, which were recorded at baseline and at weekly intervals. Tolerability was evaluated by observed/spontaneously reported adverse changes in laboratory parameters (baseline and after 4 weeks). Response rate was defined as a decrease in HAM-D score by 50% from baseline and remission rate was defined as a HAM-D score of < 8. Response rate at the end of two week were 58% for escitalopram (10mg/day), 49% for citalopram (20mg/day) and 52% for sertraline (50-100mg/day). Response rate at the end of four week were 90% for escitalopram (10-20mg/day), 86% for citalopram (20-40mg/day) and 97% for sertraline (100-150mg/day). The Remission rates at the end of four weeks were 74% for escitalopram, 65% for citalopram and 77% for sertraline. Adverse experiences were reported by 45% of patients in escitalopram group, 58% patients in citalopram and 56% patients in the sertraline group. Additionally, there were lesser dropouts and lesser requirement for dose escalation in escitalopram than in citalopram and sertraline group. In conclusion Escitalopram, the Senantiomer of the citalopram is a safe and effective antidepressant in the Indian population. It has potentially superior efficacy than citalopram and a comparable efficacy to sertraline with fewer side effects than both citalopram and sertraline.



[PDF]*

        

Print this article         Email this article